Clinical Trial

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept.
Protocol Amendment History 1 change
notable Trial sites expanded: 3 -> 11 locations 2026-08-04
Trial Details
NCT Number NCT07596901
Lead Sponsor Aurinia Pharmaceuticals Inc.
Conditions Myasthenia Gravis, Generalized
Enrollment 81 participants
Start Date 2026-04-22
Primary Completion 2029-03-02 (estimated)
Study Completion 2029-03-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-03